Q3 2017 MannKind Corp Earnings Call
Conference Call MannKind Corp
MannKind Corp Conference call or earnings call will be held on Nov 7, 2017 via an 800 number (toll-free). During the earnings conference call's session MannKind Corp will provide updated information and financial status.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact MannKind Corp for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
Unless the context requires otherwise, the words "MannKind," "we," "company," "us" and "our" refer to MannKind Corporation and its subsidiaries. MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. Our only approved product, AFREZZA, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the "FDA") on June 27, 2014 to improve glycemic control in adult patients with diabetes. AFREZZA became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, in the United States in 2012, approximately 29.1 million people had diabetes. Globally, the International Diabetes Federation has estimated that approximately 415.0 million people had diabetes in 2015 and approximately 642.0 million people will have diabetes by 2040.Read more Conference Call